EMBC
Embecta Corp.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$6.25
−4.73%Aug 26, 2026, 13:26 UTC
Bernstein Liebhard LLP announced an investigation into potential breaches of fiduciary duty by directors and officers of Embecta Corp.
Aug 12, 2026, 11:30 UTC
A class action lawsuit was filed against Embecta Corp. on behalf of investors who purchased Embecta securities between November 25, 2025 and May 4, 2026.
Aug 8, 2026, 18:00 UTC
Pomerantz LLP announced that a class action lawsuit has been filed against Embecta Corp. alleging securities fraud or other unlawful business practices by the company and certain officers and/or directors.
Aug 7, 2026, 10:30 UTC
Embecta Corp. reported its third quarter fiscal 2026 financial results on August 7, 2026.
Aug 7, 2026, 10:00 UTC
Embecta Corp.'s Board of Directors declared a quarterly cash dividend of $0.01 per share on August 7, 2026.
Source:Aug 7, 2026, 00:00 UTC
Embecta Corp. repaid approximately $53 million of debt during Q3 FY2026.
Aug 7, 2026, 00:00 UTC
Embecta Corp. repurchased approximately $9 million of its shares during Q3 FY2026 under a three-year program authorized up to $100 million.
Jul 27, 2026, 08:40 UTC
A class action lawsuit was filed against Embecta Corp. for alleged securities law violations.
Jun 25, 2026, 09:23 UTC
Embecta Corp. is sued in a securities class action lawsuit for alleged violations of the Securities Exchange Act of 1934.